Jasper Therapeutics to execute 1-for-30 reverse stock split

What happened

Jasper Therapeutics announced a 1-for-30 reverse stock split of its common stock, effective at 12:01 a.m. ET on Friday, November 6, 2026. Shares are scheduled to trade on a split-adjusted basis at that day’s market open. The company expects about 1.11 million shares outstanding afterward, versus about 33.3 million before, subject to fractional-share adjustments.

Confirmed

Global impact / market context

A reverse split combines shares, reducing the number outstanding while proportionately adjusting share-related terms. It does not by itself change the company’s total authorized common shares. The stated share-count change may alter how each share represents ownership, but the article gives no expected effect on company value or business results.

Analyst inference

The split also applies to common shares issuable through outstanding warrants and stock options, with their exercise prices adjusted proportionately. That keeps those contractual terms aligned with the reduced share count. The article does not say how the change will affect trading, financing needs, or investor demand.

Confirmed

What to watch

1. Check whether shares begin split-adjusted trading at the scheduled market open on November 6, 2026, and whether the reported share count reflects fractional-share adjustments. Confirmed
2. Look for any company updates on how the split affects outstanding warrants and stock options, including the proportionate changes to their exercise prices. Confirmed
3. Assess later disclosures for changes in financing plans or business results; the split reduces shares outstanding but does not itself establish improved operating performance. Analyst inference

Evidence

• seekingalpha.com